Spondyloarthritis & psoriatic arthritis
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis
Authors' conclusion
This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52.
Study context
- Population
- Biological disease-modifying antirheumatic drug (bDMARD)-naïve patients with r-axSpA randomised to ixekizumab (IXE) 80 mg every 4 weeks in COAST-V
- Participants
- 47 / 52 / 24
- Comparison
- Axial Spondyloarthritis Disease Activity Score (ASDAS) clinically important improvement (CII) responders vs non-responders at week 12 and/or week 24, on IXE 80 mg every 4 weeks
- CII at week 12n = 47
- CII at week 24n = 52
- No CII at week 12 or 24n = 24reference
- Primary endpoint
- ASDAS<2.1 at week 52 by ASDAS CII response at week 12 and/or week 24
- Follow-up
- Week 52
Methodological detailsphase 3, non-response imputation for missing data
- Phase 3
- Non-response imputation for missing data
Primary result
As reported in the abstract
ASDAS<2.1 at week 52
Further findings
| Outcome | CII at week 12 | CII at week 24 |
|---|---|---|
| ASDAS CII achieved | 58.0% | 64.2% |
- ASDAS CII achieved: of 81 patients
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis. RMD Open. Published 14 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →